Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sh Verma

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Current Oncology (Toronto, Ont.)|April 20, 2012
Advances in the management of metastatic breast cancer: options beyond first-line chemotherapyJ P M Ayoub, Sh Verma, Su Verma
Georgian Medical News|May 9, 2017
APLASIA CUTIS CONGENITA TYPE I - A CASE SERIESU Wollina, A Chokoeva, Sh Verma, et al.
Current Oncology (Toronto, Ont.)|August 13, 2009
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancerS Dent, Sh Verma, J Latreille, et al.
Current Oncology (Toronto, Ont.)|October 29, 2009
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancersJ Lemieux, M Clemons, L Provencher, et al.
Current Oncology (Toronto, Ont.)|August 11, 2010
Optimizing the management of HER2-positive early breast cancer: the clinical realitySu Verma, S Lavasani, J Mackey, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Current Oncology (Toronto, Ont.)|April 20, 2012
Advances in the management of metastatic breast cancer: options beyond first-line chemotherapyJ P M Ayoub, Sh Verma, Su Verma
Georgian Medical News|May 9, 2017
APLASIA CUTIS CONGENITA TYPE I - A CASE SERIESU Wollina, A Chokoeva, Sh Verma, et al.
Current Oncology (Toronto, Ont.)|August 13, 2009
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancerS Dent, Sh Verma, J Latreille, et al.
Current Oncology (Toronto, Ont.)|October 29, 2009
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancersJ Lemieux, M Clemons, L Provencher, et al.
Current Oncology (Toronto, Ont.)|August 11, 2010
Optimizing the management of HER2-positive early breast cancer: the clinical realitySu Verma, S Lavasani, J Mackey, et al.
Pageof 1